A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC)

被引:59
作者
Senkus-Konefka, E
Dziadziuszko, R
Bednaruk-Mlynski, E
Pliszka, A
Kubrak, J
Lewandowska, A
Malachowski, K
Wierzchowski, M
Matecka-Nowak, M
Jassem, J
机构
[1] Med Univ Gdansk, Dept Radiotherapy & Oncol, PL-80211 Gdansk, Poland
[2] Pomeranian Med Acad, PL-71730 Szczecin, Poland
[3] Ctr Oncol, PL-85796 Bydgoszcz, Poland
[4] Lower Silesian Oncol Ctr, PL-53413 Wroclaw, Poland
[5] Maria Sklodowska Curie Mem Canc Ctr, PL-02781 Warsaw, Poland
[6] Inst Oncol, PL-02781 Warsaw, Poland
[7] Greatpoland Canc Ctr, PL-61866 Poznan, Poland
关键词
non-small-cell lung cancer; radiotherapy; palliative treatment;
D O I
10.1038/sj.bjc.6602477
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A prospective randomised study compared two palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer (NSCLC). After stratification, 100 patients were randomly assigned to 20 Gy/5 fractions (fr)/5 days (arm A) or 16 Gy/2fr/day 1 and 8 (arm B). There were 90 men and 10 women aged 47-81 years (mean 66), performance status 1-4 (median 2). The major clinical characteristics and incidence and degree of initial disease-related symptoms were similar in both groups. Treatment effects were assessed using patient's chart, doctor's scoring of symptomatic change and chest X-ray. Study end points included degree and duration of symptomatic relief, treatment side effects, objective response rates and overall survival. A total of 55 patients were assigned to arm A and 45 to arm B. In all, 98 patients received assigned treatment, whereas two patients died before its termination. Treatment tolerance was good and did not differ between study arms. No significant differences between study arms were observed in the degree of relief of all analysed symptoms. Overall survival time differed significantly in favour of arm B (median 8.0 vs 5.3 months; P = 0.016). Both irradiation schedules provided comparable, effective palliation of tumour-related symptoms. The improved overall survival and treatment convenience of 2-fraction schedule suggest its usefulness in the routine management of symptomatic inoperable NSCLC.
引用
收藏
页码:1038 / 1045
页数:8
相关论文
共 50 条
  • [21] Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience
    Bassanelli, M.
    Giannarelli, D.
    Ricciuti, B.
    Magri, V.
    Cecere, F. L.
    Roberto, M.
    Giacinti, S.
    Barucca, V.
    Cassese, R.
    De Giglio, A.
    Scagnoli, S.
    Milella, M.
    Santarelli, M.
    Bengala, C.
    Ruggeri, E. M.
    Marchetti, P.
    Cognetti, F.
    Gelibter, A.
    Cortesi, E.
    Chiari, R.
    Ceribelli, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S611 - S611
  • [22] A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer
    Grossi, Francesco
    de Marinis, Filippo
    Gebbia, Vittorio
    Riccardi, Ferdinando
    Caffo, Orazio
    Gamucci, Teresa
    Ferrau, Francesco
    Nardi, Mario
    Moscetti, Luca
    Boni, Luca
    Dondi, Davide
    Galligioni, Enzo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 369 - 375
  • [23] A study of postoperative radiotherapy in patients with non-small-cell lung cancer: A randomized trial
    Feng, QF
    Wang, M
    Wang, LJ
    Yang, ZY
    Zhang, YG
    Zhang, DW
    Yin, WB
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (04): : 925 - 929
  • [24] Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer
    Bernstein, ED
    Herbert, SM
    Hanna, NH
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (03) : 291 - 301
  • [25] Outcomes of accelerated hypofractionated radiotherapy in stage I non-small-cell lung cancer
    Yung, T.
    Giuliani, M. E.
    Le, L. W.
    Sun, A.
    Cho, B. C. J.
    Bezjak, A.
    Brade, A.
    Hope, A. J.
    CURRENT ONCOLOGY, 2012, 19 (04) : E264 - E269
  • [26] Optimal radiotherapy for non-small-cell lung cancer: Current progress and future challenges
    Ishikura S.
    General Thoracic and Cardiovascular Surgery, 2012, 60 (3) : 127 - 131
  • [27] Symptom control and quality of life in people with lung cancer: A randomised trial of two palliative radiotherapy fractionation schedules
    Erridge, SC
    Gaze, MN
    Price, A
    Kelly, CG
    Kerr, GR
    Cull, A
    MacDougall, RH
    Howard, GCW
    Cowie, VJ
    Gregor, A
    CLINICAL ONCOLOGY, 2005, 17 (01) : 61 - 67
  • [28] Combing Immune Checkpoint Inhibitors with Radiotherapy in Advanced Non-small-cell Lung Cancer
    Zou, Y.
    Chen, Y.
    Zhou, X.
    Gong, Y.
    Xu, Y.
    Zou, B.
    Peng, F.
    Huang, M.
    Lu, Y.
    Liu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S625 - S625
  • [29] Au Nanoclusters Embedded in Polydopamine for Photothermal Radiotherapy on Non-Small-Cell Lung Cancer
    Hu, Ping
    Tian, Xiufen
    Sun, Zhiyu
    Yu, Xiaojun
    Wei, Xuguo
    Jiang, Hechun
    Wang, Xiali
    Yang, Dawei
    Jiang, Xiaohong
    ACS APPLIED NANO MATERIALS, 2024, 7 (16) : 19724 - 19736
  • [30] Assessment of palliative care for advanced non-small-cell lung cancer in France: A prospective observational multicenter study (GFPC 0804 study)
    Vergnenegre, Alain
    Hominal, Stephane
    Tchalla, Achille Edem
    Berard, Henri
    Monnet, Isabelle
    Fraboulet, Gislaine
    Baize, Nathalie
    Audigier-Valette, Clarisse
    Robinet, Gilles
    Oliviero, Gerard
    Le Caer, Herve
    Thomas, Pascal
    Geriniere, Laurence
    Mastroianni, Benedicte
    Chouaid, Christos
    LUNG CANCER, 2013, 82 (02) : 353 - 357